3-MeO-PCP

Description

3-Methoxyphencyclidine (commonly known as 3-MeO-PCP or 3-MeO) is a lesser-known novel dissociative substance of the arylcyclohexylamine class that produces dissociative, anesthetic, and hallucinogenic effects when administered. It is structurally related to arylcyclohexylamines like PCP, MXE, and 3-MeO-PCE.

3-MeO-PCP was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine (PCP) derivatives. Its activity in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle reported qualitative similarities to PCP along with comparable potency.

Like other substances of its class, particularly methoxetamine (MXE), phencyclidine (PCP), and 3-MeO-PCE, it is known to primarily induce a state referred to as “dissociative anesthesia”, although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken orally and nasally, although it may also be smoked and injected. It has been noted for its subtle come up and tendency to produce delusions of sobriety, which can lead to compulsive redosing.

Today, 3-MeO-PCP is rarely sold on the streets and almost exclusively obtained as a gray area research chemical through the use of online vendors, where it is commonly used as a recreational substance and, more rarely and controversially, as an entheogen.[citation needed] Due to its potent dissociative, stimulant and hallucinogenic effects, commonly reported habit-forming properties, as well as unknown toxicity profile, it is strongly recommended that one use proper harm reduction practices if using this substance.